Metformin has been sitting in medicine cabinets for decades, quietly managing blood sugar in millions of people with type 2 diabetes—but scientists at Université de Montréal have just cracked open one of its most tantalizing secrets. After decades of widespread use, researchers led by biochemistry professor Gerardo Ferbeyre have discovered that metformin directly targets ATP5I, a small but crucial subunit of the enzyme that powers cellular energy production. The finding, published in eLife and led by doctoral student Guillaume Lefrançois, finally answers a question that has puzzled the scientific community: how does this century-old drug actually work?
The discovery matters because epidemiological studies have long suggested that metformin may reduce cancer risk and even extend lifespan in animals—yet until now, nobody understood the mechanism. ATP5I is part of F1Fo-ATP synthase, the essential mitochondrial enzyme responsible for producing ATP, the energy-carrying molecule that fuels every cell in living organisms. Unlike other components of this enzyme, ATP5I doesn't directly drive the chemical reaction that makes ATP; instead, it appears to contribute to how the enzyme assembles and organizes itself—a subtle but pivotal role that metformin directly influences.
The UdeM team tested their hypothesis by creating cell models that lacked ATP5I entirely. These cells became resistant to metformin's effects. But when the researchers restored ATP5I, the drug's sensitivity returned—a clean, reproducible result that pointed definitively to ATP5I as metformin's direct target. Working across disciplines, chemistry professor Andreea Schmitzer and pharmacy professor Simon-Pierre Gravel brought their expertise in bioorganic chemistry and cancer metabolism to bear, combining strengths that revealed something previously invisible: how metformin doesn't simply block a cellular function, but fundamentally reshapes the architecture of the cell's energy machinery.
The implications ripple outward in multiple directions. This discovery opens new pathways to understanding how metformin might prevent cancer, extend lifespan, or work in diabetes management—but it also raises as many questions as it answers. How does metformin's binding to ATP5I translate into such broad beneficial effects across multiple diseases? Could other compounds be designed to target ATP5I in new therapeutic ways? Ferbeyre acknowledged the magnitude of the unknowns ahead: "We have opened a Pandora's box, and we will be very busy discovering where it leads us."
What makes this research particularly striking is that it concerns a compound known for over a century. Metformin was first synthesized in the 1920s and approved as a diabetes medication in the 1950s, yet it has continued to yield scientific surprises. The discovery sits at the intersection of disciplines—biochemistry meeting cell biology, chemistry meeting cancer research—a creative collision that Schmitzer credits as essential to seeing what others had missed. As researchers now understand metformin's action at the molecular level, they can begin asking deeper questions about how targeting ATP5I might unlock new therapeutic strategies, whether for aging, cancer prevention, or diseases yet to be connected to this fundamental energy-producing machinery.